Furthermore, a retrospective study focusing on CP inflammation's impact on MS progression revealed that MS patients had notably larger CP volumes and elevated CP pseudo-T2 (pT2) levels at baseline compared to healthy individuals [70]. This evidence concerns the gene CP and myeloid sarcoma.